Invention Grant
- Patent Title: Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
- Patent Title (中): CDK 4/6和FLT3的融合三环双重抑制剂
-
Application No.: US13425817Application Date: 2012-03-21
-
Publication No.: US08623885B2Publication Date: 2014-01-07
- Inventor: Xiaoqi Chen , Kang Dai , Jason Duquette , Michael W. Gribble, Jr. , Justin N. Huard , Kathleen S. Keegan , Zhihong Li , Sarah E. Lively , Lawrence R. McGee , Mark L. Ragains , Xianghong Wang , Margaret F. Weidner , Jian Zhang
- Applicant: Xiaoqi Chen , Kang Dai , Jason Duquette , Michael W. Gribble, Jr. , Justin N. Huard , Kathleen S. Keegan , Zhihong Li , Sarah E. Lively , Lawrence R. McGee , Mark L. Ragains , Xianghong Wang , Margaret F. Weidner , Jian Zhang
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen Inc.
- Current Assignee: Amgen Inc.
- Current Assignee Address: US CA Thousand Oaks
- Agent Bernard P. Friedrichsen
- Main IPC: A61K31/505
- IPC: A61K31/505 ; C07D487/12
Abstract:
Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
Public/Granted literature
- US20120244110A1 FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 Public/Granted day:2012-09-27
Information query
